May 13, 20205 yr 1 minute ago, lynched1 said: So unlike any of the other 44 presidents. The man knows no bounds. All Trump cares about is legacy. That’s why he spends all day tweeting about the media during a pandemic.
May 13, 20205 yr 3 minutes ago, Dave Moss said: All Trump cares about is legacy. That would differ how? The libraries we build for them aren't to encourage literacy. The libraries are monuments to themselves. They don't even care where you want them.
May 13, 20205 yr Daily Update https://www.nothingbutthetruthmd.com/2020/05/51220-update.html Good evening, 82,105 good reasons to wear a mask MORE ON ANTIBODIES Covid-19 and Post Infection Immunity JAMA Network Robert D. Kirkcaldy, MD. MPH Medical Epidemiologist of STD Prevention at the CDC National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Many human infections with other viral pathogens such as influenza virus do not produce a durable immune response. Whether immunity occurs among individuals after they recover from Covid-19 is uncertain. Understanding whether, and how recovery from Covid-19 confers immunity or decreased severity of reinfection is needed to inform current efforts to reopen society. Following infection with SARS-CoV-2 infection, detectable IgM and IgG antibodies develop within days to weeks of symptom onset, in most, but not all, infected individuals. Why some patients seem to develop a humoral response as reflected by detectable levels of antibodies is unknown at this time. The relationship between recovery and antibody response/level has not been determined. A small study of antibody level and clinical severity seemed to demonstrate a relationship between antibody level and the severity of the disease. This relationship however has not always corresponded with clinical improvement. Sometimes, mild Covid-19 symptoms resolve prior to an antibody response. It seems fairly certain that the viral burden peaks early in the illness and then declines as antibodies develop and antibody titres rise. This seems to be consistent with findings from Taiwan and South Korea, that infectious virus seems to be absent after about eight days of clinical symptoms. Fragments of viral RNA may be present in sufficient quantity to elicit a positive RT-PCR test however. The durability of neutralizing antibody (IgG) against SARS-CoV-2 has not been defined; persistence up to 40 days from symptom onset has been described. Antibody against SARS, (primarily IgG) remained high for about four to five months before slowly declining over two to three years. Against MERS, antibodies have persisted up to 34 months. Detection of IgG is not synonymous with durable immunity. A small study involving monkeys demonstrated resistance to infections with Covid-19 for 28 days. Reinfection with three of the four common human coronavirus has been demonstrated. To date there are no confirmed cases of reinfection with SARS-CoV-2. Viral shedding 10 to 20 days after negative RT-PCR and clinical recovery has been seen, but the clinical significance of this is unknown. (again this is thought to be secondary to shedding of non-infectious fragments of viral RNA) Serologic assays for SARS-CoV-2 are rapidly becoming available and may be beneficial in determining prevalence of infection among the asymptomatic. It is premature to use such assays to confirm immunity to re-infection. Performance standards to determine false positive, false negative and cross reactivity to other coronavirus are needed. Long term, well designed, longitudinal, cohort studies of persons who have recovered from Covid-19 are needed to monitor for signs and symptoms of reinfection. Monitoring the possibility of recurrence by Private Physicians and Public Health Officials is important. Amidst the uncertainty of this Public Health crisis, thoughtful and rigorous science will be essential to inform Public Health Policy and Practice. As I inferred last night, at this time, antibody testing outside of rigorous investigative protocols, is a waste of limited health care dollars. Numbers: 1800 from Hopkins website Tests - 9,655,039 (272,785 tests performed in the last 24 hours) performing millions of tests and generating reams of data is useless unless there is a plan USA - 1,366,350 (up 1.62%, up from 1.32% the day before) New York - 338,485 (up 0.42%, down from 0.46%, 223 fewer new cases than the day before) New Jersey - 140,206 (up 0.50% down from 1.04% the day before, 648 fewer new cases than the day before) Pennsylvania - 61,310 (up 1.40%, up from 0.86% the day before) Maryland - 34,061 (up .97%, down from 3.51%, 818 fewer new cases than the day before) California - 69,716 (up 2.50%, up from .69%) South Carolina -7927 (up 3.58%) Texas - 40,909 (up 1.79%, down from 3.15%, 511 fewer new cases than the day before) World - 4,247,709 (up 2.12%, up from 1.6%) Texas still has rising bed utilization Please forward this message to others Thank you Live Safely Be Well
May 13, 20205 yr Wuhan is going to test all 11 million residents after six people tested positive recently. They supposedly went a month with no cases. Interesting
May 13, 20205 yr 6 minutes ago, lynched1 said: That would differ how? The libraries we build for them aren't to encourage literacy. The libraries are monuments to themselves. They don't even care where you want them. It’s an exercise in vanity.
May 13, 20205 yr 1 minute ago, Dave Moss said: It’s an exercise in vanity. Indeed sir. BTW How you been?
May 13, 20205 yr What’s lifting the stay at home order really going to do? Businesses still won’t be able to open and most who can will continue to work from home.
May 13, 20205 yr 9 minutes ago, lynched1 said: Indeed sir. BTW How you been? Good, man. I mean, considering... How about you?
May 13, 20205 yr 2 minutes ago, Dave Moss said: Good, man. I mean, considering... How about you? Still "Essential". Been keeping pretty busy myself. Using Corona time to finish my big project. Gave myself until the end of summer.
May 13, 20205 yr 3 hours ago, DEagle7 said: the president of Belarus has called the virus a "psychosis", just held a massive military parade, and suggested that his citizens drink vodka and go to the sauna to stay healthy. That’s next week for us.
May 13, 20205 yr Author LINK The ‘biggest challenge’ won’t come until after a coronavirus vaccine is found. Meeting the overwhelming demand for a successful coronavirus vaccine will require a historic amount of coordination by scientists, drugmakers and the government. The nation’s supply chain isn’t anywhere close to ready for such an effort. The nation is already grappling with a shortage of the specialized glass used to make the vials that will store any vaccine. Producing and distributing hundreds of millions of vaccine doses will also require huge quantities of stoppers — which are made by just a handful of companies — as well as needles and refrigeration units. Low stocks of any one of these components could slow future vaccination efforts, much as shortfalls of key chemicals delayed widespread coronavirus testing. A massive manufacturing effort is already gearing up to produce hundreds of millions of doses of promising vaccines now in late-stage trials, as scientists and the government gamble that at least one of the shots will prove safe and effective. The effort could rival the urgent national campaign to vaccinate children against polio in the 1950s. "Probably the biggest challenge will be scaling up the actual vaccine. It’s one thing to have clinical trial samples and materials in lab quantities,” said George Zorich, a pharmacy expert and CEO of ZEDPharma. "It’s another challenge actually scaling that up effectively.” Potentially making it even harder is that the U.S. is striking out on its own. The administration has snubbed an international collaboration spearheaded by the World Health Organization, while the president readies for a November election that could be a referendum on his coronavirus response. The government is already trying to avoid the costly pitfalls that have hindered the development of vaccines for emerging threats like the Zika and Ebola viruses. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, alluded to those challenges during a talk in February. Major drugmakers have been "burned” in the past, he said, when they have raced to develop vaccines for crises like Ebola outbreaks and have spent millions to expand manufacturing without ever seeing their products used. "You invest hundreds and hundreds and hundreds of millions of dollars to scale up on something that you hope might work. That’s the real glitch there,” Fauci said. "It is going to be a challenge to get a major company to do that.” This time around, the government has given nearly a billion dollars to two experimental vaccines that are hurtling through human trials. Some of the funding will support the manufacture of doses of both vaccines, in the hopes that at least one will pan out. Moderna Therapeutics, a Boston biotech company working with the National Institutes of Health on a completely new vaccine technology, has received $430.2 million in federal funds. The company said last week that it could begin phase three trials — the final, monthslong stage of vaccine development — by "early summer.” And the government gave $456.2 million to Johnson & Johnson for its experimental vaccine. "There are a lot of resources needed, from the early stages, the pre-clinical and clinical trials, to the moment it gets injected into people’s arms,” said Howard Sklamberg, a former FDA official and attorney now at Arnold & Porter. Just creating a successful vaccine within the year would be an unprecedented achievement, since the record for developing a vaccine is four years. On top of that, while vaccines have been developed for a range of other viruses, there has never been a coronavirus vaccine. HHS has assembled an initiative under the name "Project Warp Speed” to accelerate vaccine development. Spearheaded by the experienced director of FDA’s vaccine unit, Peter Marks, the project nonetheless could face hurdles. Speeding up the vaccine timeline means taking shortcuts. Some, such as letting vaccine makers forgo certain animal studies or do them in parallel with early human trials, are already underway. The government could also issue an emergency use authorization for a promising vaccine before it’s completed all the typical review steps, just as it’s done for some coronavirus tests and drugs. Health officials are still wary of promising too much. At a Thursday Senate hearing on the pandemic, Gary Disbrow — acting director of the government’s vaccine funding unit, the Biomedical Advanced Research and Development Authority — resisted Sen. Mitt Romney’s (R-Utah) repeated questions about whether achieving a vaccine this year was reasonable. "I’m not a betting person, but if we don’t set lofty goals we won’t achieve those goals,” said Disbrow, who took the role just weeks ago after his predecessor Rick Bright was abruptly ousted. Marks hopes to have a vaccine ready in nine months, he said last week at an Axios event. "What could make that possible is really taking away dead space in the development process and taking risks that one normally would not take,” he said, referring to massive manufacturing expansions while vaccines are still in phase three trials. "The thing that is very important with vaccines is FDA has to be very sure that they are safe and effective. Unlike with drugs, you’re administering them to healthy people,” Sklamberg said. "So FDA is not going to cut corners and say, ‘We’re not sure of the safety of this one but we’re going to give it a ride.’” Then there are the supplies needed to package and distribute the vaccine itself. Each dose requires a vial, stopper, cap and packaging that keeps it stable through shipping. While the glass used for vials does not affect the vaccine, the stoppers are tricky: Manufacturers have to choose the right material, usually rubber or latex, that will not interact with the sensitive chemicals inside the vial. And in both cases, vials and stoppers, a vaccine manufacturer cannot just switch to a slightly different product or another brand. They typically have to run manufacturing changes by FDA first, which could make quick supplier changes to curb shortages a difficult prospect. The FDA can decide how flexible it will be about this type of change, says Sklamberg. The agency said in a December 2017 draft guidance that companies could note some changes in their annual reports rather than waiting for approval, but it has not finalized the policy. The ability to switch products could be crucial as the entire world readies for a possible vaccine and vies to secure their supplies. The stopper business is not a very crowded field. A Pennsylvania company called West Pharmaceutical Services is one of the dominant players, churning out millions of products a day at 25 sites worldwide. Another major producer, Schott, is based in Germany. Both companies also make glass vials, a market with a bit more competition both in the U.S. and globally — India is a major producer, said Zorich. But a medical glass shortage was already setting in before the Covid-19 pandemic emerged this year because of sand shortages in the U.S., Evercore analyst Vijay Kumar wrote in an investor note. Desert sand is too smooth to use, necessitating "angular” sand from river beds and mining that has been difficult to procure because of environmental laws and restrictions, he wrote. Glass shortages are already on the U.S. government's radar, according to ousted Bright’s 60-plus page whistleblower complaint against the administration. Bright alleges he warned of a looming global shortage of glass vials but administration officials did not heed his advice. He wrote that major glass producers have warned that a particular material, borosilicate tubing, is sold out and it could take up to two years to meet the U.S. vaccine need alone. Some manufacturers are already preparing for this potential crunch: Moderna is exploring both single-use vials and those that can hold multiple vaccine doses, according to its regulatory filings. Neither Moderna nor Johnson & Johnson immediately responded to requests for comment. A shortage of vials could interfere not just with the availability of a coronavirus vaccine but a range of other medicines, including sedatives and other drugs administered in hospitals. Government efforts to avert shortages would have to begin soon if they involve enlisting more manufacturers. "Not all glass is the same,” said Sklamberg. "A manufacturer making champagne glasses can’t just switch to making medical vials.” The coming manufacturing push for vaccines and related supplies could eclipse the scramble for masks, ventilators and tests. "We have the capacity to do this," Sklamberg said. "It’s just a lot of moving parts, organization and resources."
May 13, 20205 yr 🤔 I wonder if it has anything to do with the fact that only a very small portion of people truly want to reopen everything?
May 13, 20205 yr 2 minutes ago, Smokesdawg said: 🤔 I wonder if it has anything to do with the fact that only a very small portion of people truly want to reopen everything? Well I trust MSNBC's data/charts/graphs about as much as I trust the ones from FOX.
May 13, 20205 yr 2 hours ago, lynched1 said: So unlike any of the other 44 presidents. The man knows no bounds. It actually does differ. Significantly. But keep trying to pretend your dope boy can hang with George, Abe, Frank, Teddy.. or even Polk, Harrison, Calvin.. Harding might let Trump shine his shoes. But he'd make him fetch his shine box first.
May 13, 20205 yr 8 minutes ago, JohnSnowsHair said: It actually does differ. Significantly. The world in your mind...…….. On the bright side I don't have live there. Carry on sprout.
May 13, 20205 yr 1 hour ago, Eaglesfandan said: Well I trust MSNBC's data/charts/graphs about as much as I trust the ones from FOX. So you don’t trust the data from msnbc that shows a Republican governor with the highest approval rating??
May 13, 20205 yr DeWine’s strength is that he listens to his experts like Amy Acton. Sure, there’s been pushback, but they had a plan and stuck to it.
May 13, 20205 yr 5 hours ago, lynched1 said: The world in your mind...…….. On the bright side I don't have live there. Carry on sprout. Oh yeah we have lots of evidence of previous presidents literally stating "it's not my responsibility" when it comes to leadership and issues during a crisis. Yup. Go with that.
May 13, 20205 yr 5 minutes ago, DBW said: savageape (@savag3ap3) Tweeted: Who the hell did this 🤣🤣 https://t.co/rCLyOmsXt6
May 13, 20205 yr Wow, PA officials pulled their own family from nursing homes while forcing others to accept rona patients. These people are insidious.
May 13, 20205 yr Tom Cotton with a good run down of the democrats latest "relief package." These people are insidious.
Create an account or sign in to comment